CA
NZ
UK
AU
IND
US
Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares closed at USD 145.04 on October 23, 2026, down 7.07%. The company's most recent quarterly report on file is its Form 10-Q for the period ended June 30, 2026, filed on August 10.
Corcept Therapeutics Incorporated (NASDAQ: CORT) shares closed at USD 85.86 on October 23, 2026, down 20.13%. The commercial-stage biopharmaceutical company began selling its ovarian cancer drug Lifyorli in April, resubmitted its relacorilant application for hypercortisolism to the FDA on June 17 and reported second …
Parabilis Medicines, Inc. (NASDAQ: PBLS) shares closed at USD 24.44 on October 23, 2026, down 9.21%. The clinical-stage company completed its initial public offering in June and filed its first quarterly report as a public company for the period ended June 30, 2026.
Tango Therapeutics, Inc. (NASDAQ: TNGX) shares closed at USD 23.34 on October 23, 2026, down 16.43%. The oncology drug developer reported initial vopimetostat combination data and completed a USD 690.0 million public offering in June, then filed its second quarter 2026 report on August …
Moderna (NASDAQ:MRNA) plunged on Thursday, 22 October 2026, closing down 17.57% at $202.63, the worst performer in the S&P 500, after shares fell as much as 26% intraday on volume well above average. The move followed the leak of personalized melanoma-vaccine data on a …
● AbbVie's lutikizumab showed only a modest benefit in hidradenitis suppurativa.
● The FDA accepted the resubmission as a complete response to its November 4, 2025 letter.
● The stock reached about $0.77 after hours, which is not a closing price.
● Adjusted earnings of $0.36 a share beat the $0.24 forecast.
● KRRO-111 achieved high levels of editing of SERPINA1 messenger RNA in preclinical studies.
Please wait processing your request...